The synergistic combination of topical 5-fluorouracil (5-FU) and calcipotriol in treatment of actinic keratosis offers advantages over the use of 5-FU alone (1). These advantages include shorter treatment courses and reduced adverse effects (1) . While 5-FU is a chemotherapeutic agent, calcipotriol augments the body's own immune response against malignant and pre-malignant cells (2). A combination formulation is not yet commercially available in Australia and must be compounded, or alternatively two separate topical treatments can be prescribed (for example 5-FU plus Daivobet or Daivonex). This poster seeks to review the mechanism of action of combined therapy and identify current approaches utilised by Dermatologists within Australia. 

A survey to Fellows of the Australasian College of Dermatologists will be completed addressing prescription practices pertaining to combined 5-fluorouracil and calcipotriol.

Topical 5-fluorouracil and calcipotriol combination treatment represents a recent advance in the management of actinic keratosis. This poster will address the practicalities of prescribing this treatment within Australia.